Navigation Links
ExonHit Gets Regulatory Approval to Initiate a Phase 2 Clinical Trial for EHT 0202 in Alzheimer's Disease
Date:12/20/2007

ein), which plays a pivotal role in the evolution of Alzheimer's disease, towards a normal route. The Phase 2 trial for EHT 0202 will allow us to study this compound's therapeutic effect in Alzheimer's disease patients" underlined Professor Bruno Vellas, Department of Geriatric Medicine, Casselardit hospital, Toulouse, France.

Bruno Tocque, President of the Management Board of ExonHit said "We are delighted to initiate our Phase 2 clinical trial for EHT 0202. We also aim, through that study, to further illustrate the clinical utility of our blood-based diagnostic for Alzheimer's disease. This milestone reflects ExonHit's strategy, which is to provide therapeutic and diagnostic solutions in chronic diseases such as Alzheimer's disease".

About ExonHit Therapeutics

http://www.exonhit.com

ExonHit Therapeutics is the world's leader in the analysis of alternative RNA splicing, a process which when deregulated plays a key role in the onset of various diseases.

ExonHit has a multi-component commercial strategy to capture the maximum value from its leadership in alternative splicing. The Company is already generating revenues from a new generation of microarrays, SpliceArrayTM family of products that enable life science researchers to detect crucial disease-associated information. These products are marketed worldwide in conjunction with Agilent and Affymetrix. In the field of diagnostics, ExonHit has a major collaboration with bioMerieux to develop completely novel predictive blood-based cancer diagnostics, which could play a key role in improving the treatment of breast cancer and other major cancers and develops its own projects for the detection of other chronic diseases such as Alzheimer's disease or atherosclerosis.

In parallel, ExonHit is developing its own therapeutic pipeline in the field of neurodegenerative diseases and cancer. The Company has advanced drug candidates into
'/>"/>

SOURCE ExonHit Therapeutics SA
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
2. ExonHit Completes a Prototype to Detect Alzheimers Disease From Blood
3. Dr. Audrey F. Jakubowski of SuperGen Retires as Chief Regulatory and Quality Officer
4. FDA and Conformia Deliver Joint Presentation to Annual Regulatory and Compliance Symposium at Harvard
5. Thomson Scientific to Host Pharmaceutical Vision - A Users Conference for Information, Regulatory Affairs, Competitive Intelligence and Biotechnology Professionals
6. Cadence Pharmaceuticals Names Malvina Laudicina Vice President of Regulatory Affairs and Quality Assurance
7. Velcura Therapeutics, Inc. Appoints Industry Executive to Lead Regulatory Affairs
8. Wyeth Provides Update on Regulatory Review of Viviant (bazedoxifene)
9. Pearl Therapeutics, Inc. Expands Its Senior Management Team With Top Talent in Clinical Development and Regulatory Affairs
10. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
11. Hearing Scheduled in the Delaware Court of Chancery for August 27, 2007 to Establish the Valid Approval and Consummation of the Merger Between PharmAthene, Inc. and Healthcare Acquisition Corp.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... Your cell phone may stay charged ... storage capacity. , New research indicates that lithium-ion ... at Lawrence Livermore National Laboratory and ... components will perform as electrodes. , The growing ... for higher-performance batteries. Several key characteristics of lithium-ion ...
(Date:7/24/2014)... 2014 2014 Deep Research Report ... a professional and in-depth research report on Potassium ... basic information, including its definition, classification, application, ... research covers the international market analysis, including China’s ... covering macroeconomic environment & economic situation analysis, the ...
(Date:7/24/2014)... 24, 2014 The first part of ... in First in Human Studies” will cover comprehensive clinical ... decisions. , With increasing R&D costs and declining industry ... to maximize the knowledge collected in early Phase I/IIa ... success in late stage development. , Next, the presenters ...
(Date:7/24/2014)... As part of the long-term strategic approach, ... region during 2014 with potential global expansion. , "We ... DZS to manage our clinical trials globally and in ... R&D and President of SBI pharmaceuticals MENA, Dr. Riyadh ... a focus on utilizing eClinical software and flexible team ...
Breaking Biology Technology:Getting More Life out of Lithium-ion Batteries 2Potassium Sulphate Market & SHMP Industry 2014 (Global, China) Analysis Now Available at DeepResearchReports.com 2Potassium Sulphate Market & SHMP Industry 2014 (Global, China) Analysis Now Available at DeepResearchReports.com 3Potassium Sulphate Market & SHMP Industry 2014 (Global, China) Analysis Now Available at DeepResearchReports.com 4Best Practices for Optimizing Dose Escalation in First in Human Studies, New Webinar August 6th Hosted by Xtalks 2SBI Pharmaceuticals Co. Ltd. Enters into Preferred Provider Agreement with DZS Clinical Services 2
... 2011 Abaxis, Inc. (Nasdaq: ABAX ), ... for the medical, research and veterinary markets, announced today ... APS, ("SMB"), a privately-held developer and manufacturer of point-of-care ... based in Copenhagen, Denmark, has been the original equipment ...
... DIEGO, Feb. 10, 2011 Neurocrine Biosciences, Inc. (Nasdaq: ... year ended December 31, 2010. For the fourth ... or $0.05 per basic share, compared with a net loss of ... in 2009. For the year ended December 31, 2010, the Company ...
... - YM BioSciences Inc. (NYSE Amex: YMI, TSX: YM), ... portfolio of promising hematology and cancer-related products at various ... for the second quarter of fiscal 2011, ended December ... Hematology Annual Meeting in December 2010, we presented interim ...
Cached Biology Technology:Abaxis Makes $2.8 Million Equity Investment in Scandinavian Micro Biodevices APS 2Abaxis Makes $2.8 Million Equity Investment in Scandinavian Micro Biodevices APS 3Abaxis Makes $2.8 Million Equity Investment in Scandinavian Micro Biodevices APS 4Neurocrine Biosciences Reports Fourth Quarter and Year End 2010 Results 2Neurocrine Biosciences Reports Fourth Quarter and Year End 2010 Results 3Neurocrine Biosciences Reports Fourth Quarter and Year End 2010 Results 4Neurocrine Biosciences Reports Fourth Quarter and Year End 2010 Results 5Neurocrine Biosciences Reports Fourth Quarter and Year End 2010 Results 6Neurocrine Biosciences Reports Fourth Quarter and Year End 2010 Results 7YM BioSciences Reports Fiscal Second Quarter 2011 Operational and Financial Results 2YM BioSciences Reports Fiscal Second Quarter 2011 Operational and Financial Results 3YM BioSciences Reports Fiscal Second Quarter 2011 Operational and Financial Results 4YM BioSciences Reports Fiscal Second Quarter 2011 Operational and Financial Results 5YM BioSciences Reports Fiscal Second Quarter 2011 Operational and Financial Results 6YM BioSciences Reports Fiscal Second Quarter 2011 Operational and Financial Results 7YM BioSciences Reports Fiscal Second Quarter 2011 Operational and Financial Results 8YM BioSciences Reports Fiscal Second Quarter 2011 Operational and Financial Results 9
(Date:7/24/2014)... biodiversity and one of the most species richness biome ... However, current levels of diversity might be still underestimated. ... in the description of new endemic species of this ... availability of samples for DNA analysis. , Using ... morphological analysis, researchers from the University of Richmond ...
(Date:7/24/2014)... life arose have been maintained in our cells today according ... published today in the Journal of Biological Chemistry ... in animals still perform ancient reactions thought to have been ... years ago. , The primordial soup theory suggests that life ... the combination of metals, gases from the atmosphere and some ...
(Date:7/24/2014)... This news release is available in German . ... much welcomed in Norway and they are a common sight ... so that electric cars topped the list of new vehicle ... to the situation in Germany, where electric vehicles claim only ... cars on the roads in Germany, only a mere 8000 ...
Breaking Biology News(10 mins):A tiny new species of frog from Brazil with a heroic name 2Nano-supercapacitors for electric cars 2Nano-supercapacitors for electric cars 3
... ropes are used by kids for fun and by athletes ... jump ropes work? Can important engineering principles be studied? ... built themselves a robotic jump rope device that controls all ... length, and the distance between "hands." They capture the motion ...
... November 21, 2010 -- Airplanes do not look much like ... bird or a very strange plane -- but should they? ... California and South Africa inadvertently answered recently when they set ... order to make airplanes more fuel efficient. The modern ...
... 2010 -- From a baby,s first blurted "bowl!," for the ... the capacity for complex vocalizations is one of humankind,s most ... most of our lives. Not so for people ... who suffer the social stigma of affected speech. Nor so ...
Cached Biology News:Should airplanes look like birds? 2Air flows in mechanical device reveal secrets of speech pathology 2
ANTI CORTIS BIN GLOB...
MOUSE ANTI BOVINE WC1:FITC Immunogen: Bovine lymphocytes...
ANTI S. ENTERID LPS...
... This DuoSet ELISA Development kit contains ... of sandwich ELISAs to measure natural and ... and serum. Each kit contains sufficient materials ... plates, provided that the following conditions are ...
Biology Products: